

Cardio Diagnostics Holdings, Inc. (CDIO)

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001870144

Cardio Diagnostics Holdings, Inc. CDIO; healthcare		
Grade	None 4 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025	
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	under \$12.5M assets total assets \$7.8M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	thin data, degenerate inputs not computable: dilution, short runway, distress, fortress balance sheet	
Inputs computable	4 of 14	
Graded from	filings received through Mar 13, 2026 210 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026	
Last close	\$1.86 2026-10-08; market equity \$0	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 13, 2026

"we," "us" or the "Company" refer to Cardio Diagnostics Holdings, Inc. References to our "management" or our "management team" refer to the officers and directors of Cardio Diagnostics Holdings, Inc. a series of products for major types of cardiovascular disease and associated co-morbidities, including coronary heart disease ("CHD"), stroke, heart failure and diabetes, by leveraging our Artificial Intelligence ("AI")-driven Multi-Omics Engine? (formerly known as our AI-Integrated Genetic-Epigenetic Engine™). As a company, we aspire to give every American adult insight into their unique risk for various cardiovascular diseases.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 46.6						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(8.4%)	(6.6%)	46.6	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 34.0						
Twelve-month failure probability		not computable	0.07%			firm-wide XBRL shares cannot be assigned to one ticker class
Altman Z double-prime		(4.17)	(0.31)	50.9	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		9.79x	2.96x	17.0	839	2025-12-31
Growth and financing, sleeve percentile 35.8						
Revenue growth, three-year compound		not computable	10.0%			current value must be positive and the base must exceed \$100,000
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 3
Reinvestment rate		not computable	37.1%			required facts have no common fiscal period end
Asset growth, three years		7.5%	2.1%	35.8	704	2025-12-31
Net share issuance, one year		not computable	2.5%			firm-wide XBRL shares cannot be assigned to one ticker class

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	4 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(53.4%)	8.0%	12
Distance from 52-week high	(71.6%)	(31.4%)	11
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.98)	(0.14)	12

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$0
Operating cash flow, four quarters	-\$5.7M
Months of runway	not finite
Days since last periodic filing	63 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	\$48,150

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$6.5M	2025-12-31	2026-03-13	10-K	0001553350-26-000023
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$5.7M	2025-12-31	2026-03-13	10-K	0001553350-26-000023
3	assets	us-gaap:Assets	\$7.8M	2025-12-31	2026-03-13	10-K	0001553350-26-000023
4	assets	us-gaap:Assets	\$10.6M	2024-12-31	2026-03-13	10-K	0001553350-26-000023
5	current assets	us-gaap:AssetsCurrent	\$5.9M	2025-12-31	2026-03-13	10-K	0001553350-26-000023
6	current liabilities	us-gaap:LiabilitiesCurrent	\$604,839	2025-12-31	2026-03-13	10-K	0001553350-26-000023
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$29.2M	2025-12-31	2026-03-13	10-K	0001553350-26-000023
8	operating income	us-gaap:OperatingIncomeLoss	-\$6.5M	2025-12-31	2026-03-13	10-K	0001553350-26-000023
9	book equity	us-gaap:StockholdersEquity	\$7.0M	2025-12-31	2026-03-13	10-K	0001553350-26-000023
10	liabilities	us-gaap:Liabilities	\$793,061	2025-12-31	2026-03-13	10-K	0001553350-26-000023
11	interest expense	us-gaap:InterestExpense	\$14,801	2025-12-31	2026-03-13	10-K	0001553350-26-000023
12	revenue	us-gaap:Revenues	\$14,825	2025-12-31	2026-03-13	10-K	0001553350-26-000023
13	revenue	us-gaap:Revenues	\$34,890	2024-12-31	2026-03-13	10-K	0001553350-26-000023
14	revenue	us-gaap:Revenues	\$17,065	2023-12-31	2025-03-20	10-K	0001079973-25-000428
15	revenue	us-gaap:Revenues	\$950	2022-12-31	2024-04-01	10-K	0001079973-24-000480
16	assets	us-gaap:Assets	\$4.5M	2023-12-31	2025-03-20	10-K	0001079973-25-000428
17	assets	us-gaap:Assets	\$6.2M	2022-12-31	2024-04-01	10-K	0001079973-24-000480